Cargando…
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo
AIMS: We assessed to what degree smokers who fail to quit on the target quit date (TQD) or lapse following TQD eventually achieve success with continued treatment. DESIGN: A secondary analysis of pooled data of successful quitters treated with varenicline (306 of 696), bupropion (199 of 671) and pla...
Autores principales: | Gonzales, David, Jorenby, Douglas E, Brandon, Thomas H, Arteaga, Carmen, Lee, Theodore C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991770/ https://www.ncbi.nlm.nih.gov/pubmed/20819082 http://dx.doi.org/10.1111/j.1360-0443.2010.03058.x |
Ejemplares similares
-
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials
por: King, David P, et al.
Publicado: (2012) -
Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm
por: Rose, Jed E, et al.
Publicado: (2017) -
Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012) -
A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates
por: Rennard, Stephen, et al.
Publicado: (2012) -
Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial
por: Gonzales, D, et al.
Publicado: (2014)